<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02903498</url>
  </required_header>
  <id_info>
    <org_study_id>UFT maintenance in GC</org_study_id>
    <nct_id>NCT02903498</nct_id>
  </id_info>
  <brief_title>The Maintenance Treatment of UFT in Advanced Gastric Cancer</brief_title>
  <official_title>Phase II Study of the Maintenance Treatment of UFT (Uracil and Tegafur) After First-line</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and tolerability of the maintenance
      treatment of tegafur-uracil (UFT) after the standard first-line chemotherapy in advanced
      gastric cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>six weeks</time_frame>
    <description>PFS is calculated from the start of treatment to disease progression or death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>six weeks</time_frame>
    <description>OS is calculated from the start to treatment to the death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events</measure>
    <time_frame>six weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>UFT treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Uracil and Tegafur</description>
  </arm_group>
  <arm_group>
    <arm_group_label>comparator</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no treatment, follow-up at regular time</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UFT</intervention_name>
    <description>UFT 360mg/m2 qd po d1-14, q3w</description>
    <arm_group_label>UFT treatment</arm_group_label>
    <other_name>Uracil and Tegafur</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed advanced or metastatic adenocarcinoma of the stomach

          -  ECOG PS 0-2

          -  At least one measurable or evaluable lesion in the first-line chemotherapy (5-FU based
             regimen: ECF/EOF/EOX/FOLFOX/XELOX) with the efficacy evaluation of non-PD

          -  Adequate hepatic,renal,heart, and hematologic functions (platelets ≥75×109/L,
             neutrophil≥1.5×109/L, hemoglobin≥80 g/L, serum creatinine ≤1.5mg/dl, total bilirubin
             ≤1.5mg/dl, and serum transaminase≤2.5×the ULN)

        Exclusion Criteria:

          -  Receiving more or more than 2 regimens of chemotherapy

          -  Pregnant or lactating women

          -  Concurrent cancer

          -  History of other malignancies except cured basal cell carcinoma of skin and carcinoma
             in-situ of uterine cervix

          -  Neuropathy, brain, or leptomeningeal involvement

          -  Clinically relevant coronary artery disease or a history of a myocardial infarction
             within the last 12 months or high risk/uncontrolled arrhythmia

          -  Uncontrolled significant comorbid conditions and previous radiotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiaodong Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 4, 2016</study_first_submitted>
  <study_first_submitted_qc>September 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2016</study_first_posted>
  <last_update_submitted>October 11, 2016</last_update_submitted>
  <last_update_submitted_qc>October 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Xiaodong Zhu</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>disease control survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tegafur</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

